

# HEALTHCARE-ACQUIRED INFECTION: DEVICES, PHARMACEUTICALS, AND ENVIRONMENTAL PRODUCTS



HLC092B  
September 2013

Peggy Lehr  
*Project Analyst*

ISBN: 1-56965-541-3

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
REASONS FOR DOING THE STUDY	2
STUDY GOALS AND OBJECTIVES	2
SCOPE AND FORMAT	2
METHODOLOGIES AND INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2013 AND 2018 (%)</i>	8
CHAPTER 3 GLOBAL HAI OVERVIEW	10
RISKS FOR ACQUIRING HAI	10
MOST COMMON HEALTHCARE-ASSOCIATED INFECTIONS	11
<i>TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS</i>	12
GRAM-POSITIVE BACTERIA	13
S. AUREUS	13
Transmission Routes	13
MRSA	13
Transmission Routes	14
PNEUMONIA	14
Pseudomonas Aeruginosa	14
Hospital-Acquired Pneumonia (HAP)	14
K. Pneumonia	14
CLOSTRIDIUM DIFFICILE	15
MYCOBACTERIUM TUBERCULOSIS	15
TB Funding	15
Scope of Infection	15
Multi-Drug Resistant Tuberculosis (MDR-TB)	16
E. COLI	16
UTI Treatment Options	16
GASTROENTERITIS-CAUSING BACTERIA	17
Treatment Options	17
VANCOMYCIN-RESISTANT ENTEROCOCCI (VRE)	17
Types of VRE	17
LEGIONELLA BACTERIA	17
Treatment Options	18
GRAM-NEGATIVE BACTERIA	18
PSEUDOMONAS AERUGINOSA	18
ACINETOBACTER BAUMANNII	18
CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE)	19

<b>TOPIC</b>	<b>PAGE NO.</b>
VIRAL INFECTIONS	19
HEPATITIS B AND C	19
Scope of Infection	19
Treatment	20
HIV	20
Treatment	20
NOROVIRUS	20
INFLUENZA VIRUS	21
Influenzavirus A, B, C	21
Transmission	21
Symptoms	21
Treatment	21
FUNGAL INFECTIONS	22
ASPERGILLUS INFECTIONS	22
Treatment	22
YEAST INFECTIONS	22
Candida Infections	23
PREVENTING HAI	23
DETERMINING THE MODE OF TRANSMISSION	23
ROLES OF HEALTHCARE INSTITUTIONS AND INFECTION CONTROL INDIVIDUALS	24
<i>TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS</i>	24
COMPONENTS OF A HAI SURVEILLANCE SYSTEM	26
<i>TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM</i>	26
HEALTHCARE INFECTION POINTS OF GENERATION	27
HOSPITAL	27
Hospital Surgical Procedures	27
AMBULATORY SURGERY CENTERS IN THE U.S.	27
Infection Control in ASCs	28
DIALYSIS CENTERS	28
Transmission of VRE in Dialysis Centers	28
Hepatitis Transmission in Dialysis Centers	29
ASSISTED LIVING/LONG-TERM CARE FACILITIES	29
PROACTIVE TREATMENTS	29
THE IMPORTANCE OF HAND WASHING	29
CDC RECOMMENDATIONS FOR PREVENTION	30
<i>TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS</i>	30
<i>TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013</i>	32
<i>TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2010 (%)</i>	32
ENVIRONMENTAL CONTROLS	32
DEVICE DESIGN	33
HUMAN AND MONETARY COSTS OF HAI	33
U.S. HEALTHCARE SPENDING	33
U.S. HEALTHCARE SPENDING AND HAI	33
EMRA	34
ASIA	34

<b>TOPIC</b>	<b>PAGE NO.</b>
India	34
Japan	34
Rate of Infection	35
CHINESE MARKET	35
CHANGES IN THE INDUSTRY	36
<i>TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 (\$ MILLIONS)</i>	36
CHAPTER 4 HAI PHARMACEUTICAL MARKET	39
PHARMACEUTICALS USED FOR HAI	39
<i>TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	39
VIRAL HAI PHARMACEUTICALS	40
<i>TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2010</i>	40
VIRAL PHARMACEUTICAL MARKET BY COMPANY	41
<i>FIGURE 1 ESTIMATED GLOBAL MARKET SHARES OF HEPATITIS PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2012 (%)</i>	41
<i>FIGURE 2 ESTIMATED GLOBAL MARKET SHARES OF HIV PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2012 (%)</i>	42
<i>FIGURE 3 GLOBAL MARKET SHARES OF HAI VIRAL PHARMACEUTICALS BY TYPE OF DISEASE, 2012 (%)</i>	43
VIRAL PHARMACEUTICAL MARKET BY CONDITION	43
<i>TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2018 (\$ MILLIONS)</i>	44
BACTERIAL HAI	44
THE THREAT OF ANTIBIOTIC RESISTANCE	44
THE MICROBIOLOGY OF BACTERIAL RESISTANCE	44
MECHANISMS OF RESISTANCE	45
METHODS OF RESISTANCE	45
Beta-Lactamase Production	45
Importing Resistance from Other Organisms	46
Alteration of Binding Sites to Circumvent Anti-infective Effectiveness	47
Antibiotic Discharge	47
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE	47
Incomplete Course of Prescribed Medicine	47
Overuse of Broad-Spectrum Antibiotics	47
Antibiotics and Food Production Animals	48
Patient Pressure	48
RESISTANCE BY CLASS OF ANTIBIOTIC	48
<i>TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED</i>	49
BACTERIAL HAI PHARMACEUTICALS	49
<i>TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2012</i>	49
CLASSES OF DRUGS	50
Aminoglycosides	50
B-lactam Antibiotics	51
Cephalosporins	51
Glycopeptides	52
Lincosamides	52

<b>TOPIC</b>	<b>PAGE NO.</b>
Lipopeptides	52
Carbapenems	52
Penicillins	53
Polypeptides	53
Macrolides	53
Quinolones	53
Tetracyclines	54
Sulfonamides	54
Other Formulations	54
New Treatment for Tuberculosis	54
GLOBAL MARKET SHARE FOR BACTERIAL PHARMACEUTICALS BY COMPANY	54
<i>FIGURE 4 ESTIMATED GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2012 (%)</i>	54
<i>TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH 2018 (\$ MILLIONS)</i>	56
FUNGAL HAI PHARMACEUTICALS	56
<i>TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2012</i>	56
<i>TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2018 (\$ MILLIONS)</i>	57
<i>FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI BY COMPANY, 2012 (%)</i>	57
GLOBAL OPPORTUNITIES	58
GLOBAL GROWTH RATES FOR PHARMACEUTICALS	58
ROLE OF EMERGING COUNTRIES IN GLOBAL MARKETS	58
PHARMACEUTICAL SALES IN EMERGING NATIONS	58
REGIONAL ANALYSIS	59
<i>TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	59
AMERICAS	59
<i>TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	60
<i>TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	60
<i>FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)</i>	60
EMRA	61
<i>TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	62
<i>TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	63
<i>FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)</i>	64
ASIA	64
Hepatitis in Asian Region	65
Hepatitis in Japan	65
Hepatitis in China	65

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI, THROUGH 2018 (\$ MILLIONS)</i>	65
<i>TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)</i>	66
<i>FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)</i>	66
<b>CHAPTER 5 HAI ENVIRONMENTAL TREATMENT MARKET</b>	69
<b>GLOBAL HAI ENVIRONMENTAL TREATMENT MARKET</b>	69
<i>TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	69
<b>AIR TREATMENT</b>	69
ROOM FILTRATION SYSTEMS	70
ROOM PRESSURIZATION	70
HYDROGEN PEROXIDE VAPOR (HPV)	71
ULTRAVIOLET (UV) LIGHT DISINFECTION	71
<b>WATER TREATMENT</b>	71
DESIGN OF SINKS AND OTHER WATER FACILITIES	71
<b>LEVELS OF CLEANING</b>	72
ENVIRONMENTAL CLEANING	72
DISINFECTION	72
Levels of Disinfection	72
<i>TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS</i>	73
Disinfectants	75
Phenolics	75
Oxidizing Agents	75
Halogens	75
Aldehydes	75
Ortho-phthalaldehyde (OPA)	76
Quaternary Ammonium Compounds	76
Bleach	76
Alcohols	76
<i>TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	77
<i>FIGURE 9 GLOBAL MARKET SHARES OF DISINFECTANT PRODUCTS BY TYPE, 2012 (%)</i>	77
Patient Skin Preparation Disinfectants	77
Povidone-Iodine Solutions	78
Chlorohexidine Gluconate	78
<i>TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS, THROUGH 2018 (\$ MILLIONS)</i>	79
<b>STERILIZATION SYSTEMS FOR INFECTION CONTROL</b>	79
<i>TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	79
<b>FILTRATION</b>	80
<b>CHEMICAL STERILIZATION</b>	80
EtO Sterilization	81

<b>TOPIC</b>	<b>PAGE NO.</b>
Major Manufacturers in Chemical Sterilization	81
STEAM STERILIZATION	81
<i>TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION</i>	82
Autoclaving	82
Major Players in Heat Sterilization	82
ANTIMICROBIAL COPPER SURFACE COATINGS	82
REGIONAL ANALYSIS	83
<i>TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	83
<i>FIGURE 10 GLOBAL MARKET SHARES OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)</i>	83
AMERICAS	84
<i>TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	85
<i>TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	85
EMRA	85
<i>TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	86
<i>TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	86
<i>FIGURE 11 EMRA MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)</i>	86
ASIA	87
<i>TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI, THROUGH 2018 (\$ MILLIONS)</i>	88
<i>TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	88
<i>FIGURE 12 ASIAN MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)</i>	88
CHAPTER 6 HAI MEDICAL DEVICES: CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILIZATION FILTERS	91
<i>TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)</i>	91
ANTIMICROBIAL COATINGS	91
CATHETERS	91
CATHETER COATINGS	92
Common Antimicrobial Coatings	92
Nitrofurazone	93
Minocycline/Rifampin	93
Silver Coating	93
SURFACE-MODIFIED CATHETER	93
GLOBAL HAI CATHETER MARKET	94
<i>TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES, THROUGH 2018 (\$ MILLIONS)</i>	94
<i>FIGURE 13 PROJECTED HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC, 2013 AND 2018 (%)</i>	95
URINARY TRACT CATHETERS	95

<b>TOPIC</b>	<b>PAGE NO.</b>
CENTRAL VENOUS CATHETERS	96
Dialysis Catheters	96
Catheter-Related Bloodstream Infections (CRBSI)	96
PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC)	97
MARKET OPPORTUNITIES FOR CATHETER MANUFACTURERS	97
CATHETER GROWTH IN REGIONAL MARKETS	97
<i>TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	98
<i>FIGURE 14 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2013 AND 2018 (%)</i>	98
PATIENT VENTILATION DEVICES	99
<i>TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2018 (\$ MILLIONS)</i>	100
TYPES OF VENTILATION DEVICES	100
Noninvasive Ventilators	100
PATIENT VENTILATION MARKET	101
<i>TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 (\$ MILLIONS)</i>	101
ENDOTRACHEAL TUBES AND VENTILATION SYSTEMS	101
Coated Endotracheal Tubes	101
Tapered Endotracheal Tubes	102
<i>TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2018 (\$ MILLIONS)</i>	102
IN-LINE STERILE IV FILTRATION	102
<i>TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 (\$ MILLIONS)</i>	103
REGIONAL ANALYSIS	103
<i>TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	103
<i>FIGURE 15 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2013 AND 2018 (%)</i>	104
THE AMERICAS	105
<i>TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICES BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	105
<i>FIGURE 16 AMERICAS MARKET SHARES FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, 2013 AND 2018 (%)</i>	105
<i>TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)</i>	107
<i>FIGURE 17 AMERICAS MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)</i>	107
EMRA	108
<i>TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	108
<i>TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)</i>	109
<i>FIGURE 18 EMRA MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)</i>	109
ASIA	110
<i>TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	110



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)</i>	111
<i>FIGURE 19 ASIAN MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)</i>	111
CHAPTER 7 REGULATIONS	114
AMERICAS	114
CREATING DRUG TREATMENTS	114
<i>TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.</i>	114
U.S. INFECTION CONTROL PROGRAMS	115
INFECTION CONTROL MEASURES/PROTOCOLS	115
U.S. REGULATIONS	116
HOSPITAL INFECTIONS DISCLOSURE ACT (HIDA)	116
CURRENT AND PENDING REQUIREMENTS	116
Affordable Care Act and Implications for the Pharmaceutical Industry	116
Biosimilars	117
CMS Reimbursement for HAI	117
"Never Events" Reimbursement	117
Generating Antibiotics Incentives Now Act (2012)	118
BRAZILIAN REGULATIONS	118
EUROPEAN REGULATIONS	119
INNOVATIVE MEDICINES INITIATIVE (IMI)	119
IMPLICATIONS FOR PHARMACEUTICAL MANUFACTURERS	119
JAPANESE REGULATIONS	119
CHINESE REGULATIONS	120
CHAPTER 8 CURRENT RESEARCH, EMERGING THERAPIES AND MARKET OPPORTUNITIES	122
EMERGING RESEARCH	122
FIMD	122
BROAD SPECTRUM ANTIVIRAL	122
NEW ENGLAND CENTER OF EXCELLENCE (NERCE)	123
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE	123
<i>TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE</i>	123
<i>FIGURE 20 MARKET SHARES BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2012 (%)</i>	127
PHARMACEUTICAL RESEARCH	129
BACTERIAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN DEVELOPMENT	129
Achaogen	129
Rib-X Pharmaceuticals	129
Wakamoto Pharmaceutical Co. Ltd.	129
GlaxoSmithKline (GSK)	129
Polyphor	130
Rempex Pharmaceuticals	130
Basilea Pharmaceuticals	130
Cerexa	130
Cubist Pharmaceuticals	131

<b>TOPIC</b>	<b>PAGE NO.</b>
Merck	131
Galapagos NV	131
Optimer Pharmaceuticals	132
GlaxoSmithKline	132
Toyama Chemical	132
Trius Therapeutics	132
Crestone Pharma	133
Boehringer Ingelheim	133
Theravance	133
The Medicines Company	134
Paratek Pharmaceuticals	134
<b>VIRAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN DEVELOPMENT</b>	<b>134</b>
BioCryst Pharmaceuticals	134
ViiV Healthcare	134
Roche	135
Merck	135
Toyama Chemical	135
Daiichi Sankyo	136
Gilead Sciences	136
Janssen Pharmaceuticals/Johnson & Johnson	136
Vertex	136
<b>FUNGAL INFECTIONS: APPROVED TREATMENTS AND PRODUCTS IN DEVELOPMENT</b>	<b>136</b>
Basilea Pharmaceuticals	136
<b>ANTISEPTIC WASHES</b>	<b>137</b>
<b>MEDICAL DEVICE DESIGN</b>	<b>137</b>
ANTIBACTERIAL, ANTIFOULING POLYMER COATINGS	137
ONDINE BIOMEDICAL	137
<b>OPPORTUNITIES/CHALLENGES FOR HAI INDUSTRY</b>	<b>138</b>
MEDICAL DEVICE OPPORTUNITIES/CHALLENGES	138
Challenges	138
ENVIRONMENTAL AND STRUCTURAL OPPORTUNITIES/CHALLENGES	139
Challenges	139
PHARMACEUTICAL MARKET OPPORTUNITIES/CHALLENGES	139
Patent Expiry	140
<i>TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2005-2015</i>	140
Pipeline Limitations	140
Regulatory Restrictions	141
Generic Competition	141
<b>THE IMPACT OF DEMOGRAPHIC CHANGES</b>	<b>141</b>
DEMOGRAPHIC CHANGES IN THE U.S.	141
DEMOGRAPHIC CHANGES OUTSIDE THE U.S.	142
<b>CHAPTER 9 PATENTS</b>	<b>144</b>
<i>TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013</i>	144
PATENTS BY DATE OF ISSUE	144

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013</i>	145
<i>TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013</i>	145
<i>TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013</i>	145
NUMBER OF PATENTS BY MANUFACTURER	145
<i>TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY 2013</i>	146
PHARMACEUTICALS	148
BACTERIAL PHARMACEUTICAL PATENTS	148
<i>TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013</i>	149
FUNGAL PHARMACEUTICAL PATENTS	160
<i>TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGH DECEMBER 2012</i>	160
VIRAL PHARMACEUTICAL PATENTS	160
<i>TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013</i>	161
ENVIRONMENTAL CONTROLS	162
<i>TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013</i>	163
<i>TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013</i>	164
<i>TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013</i>	165
PATENTS FOR PATIENT DISINFECTION	166
<i>TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013</i>	166
PATENTS FOR SURFACE DISINFECTANTS	167
<i>TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013</i>	167
MEDICAL DEVICES	172
<i>TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012</i>	172
Antimicrobial Coatings	176
<i>TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013</i>	177
CHAPTER 10 COMPANY DIRECTORY	187
PHARMACEUTICALS	187
ABBOTT LABORATORIES	187
Business Overview	187
Products	187
<i>TABLE 68 ABBOTT HAI PRODUCTS</i>	187
ACHAOGEN INC.	188
ASTELLAS PHARMA INC.	188
Business Overview	188

<b>TOPIC</b>	<b>PAGE NO.</b>
Products	188
<i>TABLE 69 ASTELLAS HAI PRODUCTS</i>	188
ASTRAZENECA PLC	189
Business Overview	189
Products	189
<i>TABLE 70 ASTRAZENECA HAI PRODUCTS</i>	189
B. BRAUN MELSUNGEN	189
Business Overview	189
Products	190
<i>TABLE 71 B. BRAUN HAI PRODUCTS</i>	190
BACTIGUARD AB	190
Business Overview	190
Products	190
BASILEA PHARMACEUTICA LTD.	191
Business Overview	191
Products	191
BAXTER INTERNATIONAL	191
Business Overview	191
BAYER AG (MILES-BAYER)	192
Business Overview	192
Products	192
<i>TABLE 72 BAYER HAI PRODUCTS</i>	192
BOEHRINGER INGELHEIM GMBH	192
Business Overview	193
Products	193
<i>TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS</i>	193
BRISTOL-MYERS SQUIBB	193
Business Overview	193
Products	194
<i>TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS</i>	194
CEREXA INC. (FOREST LABORATORIES)	194
Business Overview	194
Products	194
<i>TABLE 75 CEREXA HAI PRODUCTS</i>	194
CUBIST PHARMACEUTICALS	195
Business Overview	195
Products	195
<i>TABLE 76 CUBIST HAI PRODUCTS</i>	195
DAIICHI SANKYO	195
Business Overview	195
Products	196
<i>TABLE 77 DAIICHI SANKYO HAI PRODUCT</i>	196
FOREST LABORATORIES	196
Business Overview	196
Products	196
<i>TABLE 78 FOREST LABORATORIES HAI PRODUCTS</i>	196
GILEAD SCIENCES	196

<b>TOPIC</b>	<b>PAGE NO.</b>
Business Overview	197
Products	197
<i>TABLE 79 GILEAD SCIENCES HAI PRODUCTS</i>	197
GLAXOSMITHKLINE	197
Business Overview	197
Products	198
<i>TABLE 80 GLAXOSMITHKLINE HAI PRODUCTS</i>	198
JOHNSON & JOHNSON	198
Business Overview	198
Products	199
<i>TABLE 81 JOHNSON &amp; JOHNSON HAI PRODUCTS</i>	199
JANSSEN THERAPEUTICS (FORMERLY TIBOTEC THERAPEUTICS)	199
Business Overview	199
Products	200
<i>TABLE 82 JANSSEN THERAPEUTICS HAI PRODUCTS</i>	200
MERCK	200
Business Overview	200
Products	200
<i>TABLE 83 MERCK HAI PRODUCTS</i>	200
NOVARTIS PHARMACEUTICALS	201
Business Overview	201
Products	201
<i>TABLE 84 NOVARTIS HAI PRODUCTS</i>	201
PFIZER	202
Business Overview	202
Products	202
<i>TABLE 85 PFIZER HAI PRODUCTS</i>	202
REMPEX PHARMACEUTICALS	203
Business Overview	203
RIB-X PHARMACEUTICALS	203
Business Overview	203
ROCHE PHARMACEUTICALS	204
Business Overview	204
Products	204
<i>TABLE 87 ROCHE HAI PHARMACEUTICAL PRODUCTS</i>	204
ROMARK LABORATORIES	204
Business Overview	204
SCHERING-PLOUGH (SEE MERCK)	205
TETRAPHASE PHARMACEUTICALS	205
Business Overview	205
THERAVANCE	205
Business Overview	205
Products	206
<i>TABLE 88 THERAVANCE HAI PRODUCTS</i>	206
TOYAMA CHEMICAL CO. LTD.	206
Business Overview	206
Products	206

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 89 TOYAMA CHEMICAL HAI PRODUCTS</i>	206
VENUS REMEDIES LTD.	207
Business Overview	207
Products	207
<i>TABLE 90 VENUS REMEDIES HAI PRODUCTS</i>	207
VERTEX PHARMACEUTICALS INC.	207
Business Overview	207
Products	208
<i>TABLE 91 VERTEX HAI PRODUCTS</i>	208
VIIV HEALTHCARE	208
Business Overview	208
Products	208
<i>TABLE 92 VII HEALTHCARE HAI PRODUCTS</i>	208
VIROPHARMA INC.	209
Business Overview	209
Products	209
<i>TABLE 93 VIROPHARMA HAI PRODUCTS</i>	209
ENVIRONMENTAL PRODUCTS	209
3M HEALTHCARE, MEDICAL DIVISION	209
Business Overview	209
Products	210
ADVANCED STERILIZATION PRODUCTS	210
Business Overview	210
Products	210
ANDERSEN PRODUCTS INC.	211
Business Overview	211
Products	211
ECOLAB	211
Business Overview	211
Products	211
GETINGE USA INC.	212
Business Overview	212
Products	212
PRIMUS STERILIZER CO. INC.	212
Business Overview	212
Products	212
RUHOF CORP.	213
Business Overview	213
Products	213
STERIGENICS INTERNATIONAL INC.	213
Business Overview	213
Products	213
SEALED AIR CORP. (DIVERSEY INC.)	214
Business Overview	214
Products	214
STERIS CORP.	214
Business Overview	214

<b>TOPIC</b>	<b>PAGE NO.</b>
Products	214
TUTTNAUER USA CO. LTD.	215
Business Overview	215
Products	215
ULTRAVIOLET DEVICES INC.	215
Business Overview	215
Products	215
XENEX HEALTHCARE SERVICES	216
Business Overview	216
Products	216
INFECTION CONTROL DEVICES	216
B BRAUN MELSUNGEN AG	216
Business Overview	217
Products	217
BECTON DICKINSON	217
Business Overview	217
Products	217
CANTEL MEDICAL CORP.	218
Business Overview	218
Products	218
CAREFUSION CORP.	219
Business Overview	219
Products	219
CLOROX CO.	219
Business Overview	219
Products	219
COLOPLAST GROUP	220
Business Overview	220
Products	220
COOK MEDICAL	220
Business Overview	220
Products	220
COVIDIEN PLC	221
Business Overview	221
Products	221
C.R. BARD	221
Business Overview	221
Products	222
KIMBERLY-CLARK HEALTHCARE	222
Business Overview	222
Products	222
ONDINE BIOMEDICAL INC.	222
Business Overview	222
Products	223
ROCHESTER MEDICAL LTD.	223
Business Overview	223
Products	223

<b>TOPIC</b>	<b>PAGE NO.</b>
TELEFLEX MEDICAL	223
Business Overview	223
Products	224
WELCH ALLYN INC.	224
Business Overview	224
Products	224
WELLSPECT HEALTHCARE (FORMERLY ASTRA TECH INC.)	224



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR SELECTED HAI TREATMENTS, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 CAUSES AND TYPES OF HEALTHCARE-ACQUIRED INFECTIONS	12
TABLE 2 SELECTED RESPONSIBILITIES OF INFECTION CONTROL TEAM MEMBERS	24
TABLE 3 MAIN STEPS AND COMPONENTS IN DEVELOPING AN EFFECTIVE INFECTION CONTROL SURVEILLANCE SYSTEM	26
TABLE 4 CDC MEASURES FOR PREVENTION OF HEALTHCARE-ACQUIRED INFECTIONS	30
TABLE 5 GOALS TO REDUCE HAI IN U.S. HOSPITALS BY 2013	32
TABLE 6 DECREASE IN HAI IN U.S. HOSPITAL SETTINGS, 2008-2010 (%)	32
TABLE 7 SELECTED MERGERS AND/OR ACQUISITIONS, 2008-2013 (\$ MILLIONS)	36
TABLE 8 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY TYPE, THROUGH 2018 (\$ MILLIONS)	39
TABLE 9 SELECTED VIRAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2010	40
TABLE 10 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT VIRAL HAI BY CONDITION, THROUGH 2018 (\$ MILLIONS)	44
TABLE 11 ANTIBIOTIC RESISTANT ORGANISMS AND DRUG CLASSES AFFECTED	49
TABLE 12 SELECTED BACTERIAL HAI PHARMACEUTICALS BY NAME, INDICATION AND MANUFACTURER, 2012	49
TABLE 13 PROJECTED GLOBAL MARKET FOR TO TREAT BACTERIAL HAI, THROUGH 2018 (\$ MILLIONS)	56
TABLE 14 SELECT LISTING OF PHARMACEUTICALS TO TREAT FUNGAL INFECTIONS BY NAME, TYPE AND MANUFACTURER, 2012	56
TABLE 15 PROJECTED GLOBAL MARKET FOR PHARMACEUTICALS TO TREAT FUNGAL HAI, THROUGH 2018 (\$ MILLIONS)	57
TABLE 16 PROJECTED GLOBAL MARKET FOR HAI PHARMACEUTICALS BY REGION, THROUGH 2018 (\$ MILLIONS)	59
TABLE 17 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)	60
TABLE 18 PROJECTED AMERICAS MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	60
TABLE 19 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)	62
TABLE 20 PROJECTED EMRA MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)	63
TABLE 21 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS TO CONTROL HAI, THROUGH 2018 (\$ MILLIONS)	65
TABLE 22 PROJECTED ASIAN MARKET FOR PHARMACEUTICAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS BY TYPE, THROUGH 2018 (\$ MILLIONS)	66
TABLE 23 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	69
TABLE 24 ADVANTAGES/DISADVANTAGES OF COMMONLY USED DISINFECTANTS	73
TABLE 25 PROJECTED GLOBAL MARKET FOR DISINFECTANT PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	77
TABLE 26 PROJECTED GLOBAL MARKET FOR PATIENT PREPARATION DISINFECTANTS, THROUGH 2018 (\$ MILLIONS)	79
TABLE 27 PROJECTED GLOBAL MARKET FOR STERILIZATION DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	79

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 28 SELECTED MATERIALS THAT RESPOND WELL TO STEAM STERILIZATION	82
TABLE 29 PROJECTED GLOBAL MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)	83
TABLE 30 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)	85
TABLE 31 PROJECTED AMERICAS MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	85
TABLE 32 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI BY REGION, THROUGH 2018 (\$ MILLIONS)	86
TABLE 33 PROJECTED EMRA MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	86
TABLE 34 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS/EQUIPMENT TO CONTROL HAI, THROUGH 2018 (\$ MILLIONS)	88
TABLE 35 PROJECTED ASIAN MARKET FOR ENVIRONMENTAL PRODUCTS DESIGNED TO MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	88
TABLE 36 PROJECTED GLOBAL MARKET FOR MEDICAL DEVICES THAT MINIMIZE HEALTHCARE-ACQUIRED INFECTIONS, THROUGH 2018 (\$ MILLIONS)	91
TABLE 37 PROJECTED GLOBAL MARKET FOR CATHETERS WITH ANTIMICROBIAL PROPERTIES, THROUGH 2018 (\$ MILLIONS)	94
TABLE 38 PROJECTED GLOBAL HAI CATHETER MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	98
TABLE 39 PROJECTED GLOBAL MARKET FOR PATIENT VENTILATION PRODUCTS, THROUGH 2018 (\$ MILLIONS)	100
TABLE 40 PROJECTED GLOBAL MARKET FOR NONINVASIVE VENTILATION SYSTEMS FOR USE WITH PATIENTS WHO HAVE HAI, THROUGH 2018 (\$ MILLIONS)	101
TABLE 41 PROJECTED GLOBAL MARKET FOR COATED ENDOTRACHEAL TUBES DESIGNED TO MINIMIZE VAP, THROUGH 2018 (\$ MILLIONS)	102
TABLE 42 PROJECTED GLOBAL STERILE IV FILTER MARKET, THROUGH 2018 (\$ MILLIONS)	103
TABLE 43 PROJECTED GLOBAL MARKET FOR PATIENT INFECTION CONTROL DEVICES BY REGION, THROUGH 2018 (\$ MILLIONS)	103
TABLE 44 PROJECTED AMERICAS MARKET FOR HAI INFECTION CONTROL DEVICES BY REGION, THROUGH 2018 (\$ MILLIONS)	105
TABLE 45 PROJECTED AMERICAS MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)	107
TABLE 46 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 (\$ MILLIONS)	108
TABLE 47 PROJECTED EMRA MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)	109
TABLE 48 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY REGION, THROUGH 2018 (\$ MILLIONS)	110
TABLE 49 PROJECTED ASIAN MARKET FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, THROUGH 2018 (\$ MILLIONS)	111
TABLE 50 PROCESS OF CREATING DRUG TREATMENTS IN THE U.S.	114
TABLE 51 HAI PHARMACEUTICAL PRODUCT PIPELINE	123
TABLE 52 SELECTED HAI-RELATED PHARMACEUTICAL PATENT EXPIRATIONS, 2005-2015	140
TABLE 53 NUMBER OF SELECTED PATENTS BY TYPE, 2008 THROUGH JULY 2013	144
TABLE 54 PHARMACEUTICAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013	145

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 55 ENVIRONMENTAL PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013	145
TABLE 56 MEDICAL DEVICE* PATENTS BY DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013	145
TABLE 57 NUMBER OF PATENTS BY MANUFACTURER, JAN. 2008 THROUGH JULY 2013	146
TABLE 58 PATENTS ON BACTERIAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JULY 2013	149
TABLE 59 PATENTS ON FUNGAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2010 THROUGH DECEMBER 2012	160
TABLE 60 PATENTS ON VIRAL PHARMACEUTICALS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, JAN. 2008 THROUGH JULY 2013	161
TABLE 61 PATENTS ON AIR FILTRATION: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE JULY 2012-MARCH 2013	163
TABLE 62 PATENTS ON WATER TREATMENT: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE SEPT. 2010 TO JUNE 2013	164
TABLE 63 PATENTS ON SOLID WASTE TREATMENT: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE APRIL 2013	165
TABLE 64 PATENTS ON PATIENT DISINFECTANTS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013	166
TABLE 65 PATENTS ON SURFACE DISINFECTANTS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 TO JULY 2013	167
TABLE 66 PATENTS ON CATHETERS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JANUARY 2008 TO JULY 2012	172
TABLE 67 PATENTS ON ANTIMICROBIAL COATINGS: NUMBER, COMPANY, TYPE OF PHARMACEUTICAL, DESCRIPTION, DATE OF ISSUE, JAN. 2008 THROUGH JUNE 2013	177
TABLE 68 ABBOTT HAI PRODUCTS	187
TABLE 69 ASTELLAS HAI PRODUCTS	188
TABLE 70 ASTRAZENECA HAI PRODUCTS	189
TABLE 71 B. BRAUN HAI PRODUCTS	190
TABLE 72 BAYER HAI PRODUCTS	192
TABLE 73 BOEHRINGER INGELHEIM HAI PRODUCTS	193
TABLE 74 BRISTOL MYERS SQUIBB HAI PRODUCTS	194
TABLE 75 CEREXA HAI PRODUCTS	194
TABLE 76 CUBIST HAI PRODUCTS	195
TABLE 77 DAIICHI SANKYO HAI PRODUCT	196
TABLE 78 FOREST LABORATORIES HAI PRODUCTS	196
TABLE 79 GILEAD SCIENCES HAI PRODUCTS	197
TABLE 80 GLAXOSMITHKLINE HAI PRODUCTS	198
TABLE 81 JOHNSON & JOHNSON HAI PRODUCTS	199
TABLE 82 JANSSEN THERAPEUTICS HAI PRODUCTS	200
TABLE 83 MERCK HAI PRODUCTS	200
TABLE 84 NOVARTIS HAI PRODUCTS	201
TABLE 85 PFIZER HAI PRODUCTS	202
TABLE 87 ROCHE HAI PHARMACEUTICAL PRODUCTS	204
TABLE 88 THERAVANCE HAI PRODUCTS	206
TABLE 89 TOYAMA CHEMICAL HAI PRODUCTS	206
TABLE 90 VENUS REMEDIES HAI PRODUCTS	207

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 91 VERTEX HAI PRODUCTS	208
TABLE 92 VII HEALTHCARE HAI PRODUCTS	208
TABLE 93 VIROPHARMA HAI PRODUCTS	209

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET SHARES OF HAI TREATMENTS BY GEOGRAPHICAL AREA, 2013 AND 2018 (%)	8
FIGURE 1 ESTIMATED GLOBAL MARKET SHARES OF HEPATITIS PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2012 (%)	41
FIGURE 2 ESTIMATED GLOBAL MARKET SHARES OF HIV PHARMACEUTICALS TO TREAT HAI BY COMPANY, 2012 (%)	42
FIGURE 3 GLOBAL MARKET SHARES OF HAI VIRAL PHARMACEUTICALS BY TYPE OF DISEASE, 2012 (%)	43
FIGURE 4 ESTIMATED GLOBAL MARKET SHARES OF HAI BACTERIAL PHARMACEUTICALS BY COMPANY, 2012 (%)	54
FIGURE 5 GLOBAL MARKET SHARES OF PHARMACEUTICALS TO TREAT FUNGAL HAI BY COMPANY, 2012 (%)	57
FIGURE 6 AMERICAS HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)	60
FIGURE 7 EMRA HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)	64
FIGURE 8 ASIAN HAI PHARMACEUTICAL MARKET SHARES BY DISEASE TYPE, 2013 AND 2018 (%)	66
FIGURE 9 GLOBAL MARKET SHARES OF DISINFECTANT PRODUCTS BY TYPE, 2012 (%)	77
FIGURE 10 GLOBAL MARKET SHARES OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)	83
FIGURE 11 EMRA MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)	86
FIGURE 12 ASIAN MARKET SHARE OF ENVIRONMENTAL PRODUCTS TO MINIMIZE HAI BY PRODUCT, 2013 AND 2018 (%)	88
FIGURE 13 PROJECTED HAI CATHETER MARKET SHARES BY URINARY, CVC, PICC, 2013 AND 2018 (%)	95
FIGURE 14 PROJECTED GLOBAL HAI CATHETER MARKET SHARES BY REGION, 2013 AND 2018 (%)	98
FIGURE 15 GLOBAL HAI PATIENT INFECTION CONTROL DEVICES MARKET SHARES BY REGION, 2013 AND 2018 (%)	104
FIGURE 16 AMERICAS MARKET SHARES FOR CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS, 2013 AND 2018 (%)	105
FIGURE 17 AMERICAS MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)	107
FIGURE 18 EMRA MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)	109
FIGURE 19 ASIAN MARKET SHARES OF CATHETERS, PATIENT VENTILATION SYSTEMS AND IN-LINE STERILE FILTERS BY PRODUCT, 2013 AND 2018 (%)	111
FIGURE 20 MARKET SHARES BY TYPE OF PHARMACEUTICAL COMPOUND IN DEVELOPMENT, 2012 (%)	127